NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
– EMA submission expected in 2H25 by partner Menarini –
– PREVAIL Phase 3 CVOT remains on track –
-- BROADWAY and TANDEM results presented at EAS with simultaneous publications in the New England Journal of Medicine and The Lancet, respectively --
Read more at globenewswire.comNASDAQ:NAMSW (9/5/2025, 8:00:01 PM)
15.49
+1.51 (+10.8%)
27
+1.34 (+5.22%)
Find more stocks in the Stock Screener
